| Effects of pioglitazone vs metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes - a randomized controlled trial. | |
| | |
MedLine Citation:
|
PMID: 21255215 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Aim: Endothelial microparticles (EMPs) and endothelial progenitor cells (EPCs) are markers of endothelial injury and repair. We compared the effects of pioglitazone versus metformin on the circulating numbers of EMPs and EPCs in patients with newly-diagnosed type 2 diabetes. Methods: This was a randomized, double-blind, comparator-controlled, 24-week single-center trial conducted in a Teaching Hospital in Naples, Italy. One hundred and ten people with newly diagnosed type 2 diabetes who were never treated with antihyperglycemic drugs and had hemoglobin A1c (HbA1c) levels between 7 and 10%, were given Pioglitazone hydrochloride (15-45 mg/d) (n = 55) or metformin (1000-2000 mg/d) (n = 55) as an active comparator. Absolute change from baseline to final visit in circulating EMPs and EPCs, and their ratio were the primary outcomes. Results: Baseline characteristics did not differ between the study groups. The decrease of circulating EMPsCD31+ (intergroup difference, -32 counts/μL [95% CI, -51 to -9]), and the increase of EPCsCD34+KDR+ (intergroup difference, 33 cells/10(6) events [CI, 13 to 55]) was greater with pioglitazone vs metformin. EMPS/EPCs ratio was reduced with pioglitazone and unchanged with metformin (difference, -1.5 [CI, -2.6 to -0.5], P < 0.001). Participants assigned to pioglitazone gained more weight and experienced greater improvements in some coronary risk measures (HDL-cholesterol, triglycerides, adiponectin, and C-reactive protein) than did those assigned to metformin. Conclusion: Compared with metformin, pioglitazone treatment improved the imbalance between endothelial damage and repair capacity, and led to more favorable changes in coronary risk factors in patients with newly-diagnosed type 2 diabetes. |
| | |
Authors:
|
K Esposito; M I Maiorino; C Di Palo; M Gicchino; M Petrizzo; G Bellastella; F Saccomanno; D Giugliano |
Related Documents
:
|
17703435 - Short- and long-term glycaemic control and the state of the renin system in type 1 diab... 2528845 - Activation of blood coagulation and fibrinolysis in diabetes mellitus: evaluation by pl... 19273745 - Vascular-protective effects of high-density lipoprotein include the downregulation of t... 17699555 - Downregulation of trpc6 protein expression by high glucose, a possible mechanism for th... 15811195 - Ppargamma and atherosclerosis. 19258435 - Diabetes incidence based on linkages with health plans: the multiethnic cohort. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-1-21 |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: - ISSN: 1463-1326 ISO Abbreviation: - Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-1-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2011 John Wiley & Sons A/S. |
Affiliation:
|
1Department of Geriatrics and Metabolic Diseases, Azienda Universitaria Policlinico, Second University of Naples, Naples, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Superfolder GFP is fluorescent in oxidizing environments when targeted via the Sec translocon.
Next Document: JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresse...